Lewy Bodies Study--Assessing the Effects of a Drug Called RVT-101
Official Title
A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)
Purpose
Purpose of Study:
This research study is being done to test a drug called RVT-101. Our researchers want to assess the effects of RVT-101 versus placebo on function including attention, working memory, reaction time, as well as other measures of cognition in patients with DLB.
RVT-101 is an investigational drug. Investigational means that the drug tested in this study has not been approved by the U.S. Food and Drug Administration (FDA) or any other Health Authority including European or Canadian Health Authorities.
Could this study be right for you?
- Ages 50-85
- Diagnosis of Probable dementia with Lewy bodies
- Must have a study partner willing to attend visits and ensure compliance with the study
- Score on MMSE of 14-26 (Mini–Mental State Examination--the study coordinator can explain this)